Show simple item record

dc.contributor.authorMaraiki, Fatma
dc.contributor.authorByrnes, J
dc.contributor.authorTuffaha, H
dc.contributor.authorHinder, M
dc.date.accessioned2019-09-20T02:54:24Z
dc.date.available2019-09-20T02:54:24Z
dc.date.issued2019
dc.identifier.issn2509-4262
dc.identifier.doi10.1007/s41669-018-0088-x
dc.identifier.urihttp://hdl.handle.net/10072/387573
dc.description.abstractOBJECTIVES: The aim of this study was to compare the listing success rates and time incurred to listing of recently approved lung cancer medications across Australia, Canada and England. METHODS: A comparison between the three countries was performed with respect to the listing status, time incurred for listing and differences in recommendations made for cost effectiveness. Major uncertainties and limitations that compromise health technology assessment (HTA) recommendations were identified. RESULTS: The listing success rate was found to be low across all three countries (33% Canada, 17% England and 8% Australia). Across the HTA agencies' reviews, comparators were either dissimilar or altered for effectiveness and/or economic analysis. Overall, limited evidence was found for all indications, and uncertainties were identified due to indirect analyses (70%) and survival extrapolation (100%). Although most of the indications were concluded to be not cost effective, some were subsequently listed (47%) at a reduced price and/or with a specific access programme. CONCLUSIONS: This study demonstrated a low listing success rate for novel lung therapies internationally within different HTA jurisdictions. Major uncertainties that are resistant to available solutions seem to be common across different countries; thus, international solutions would be beneficial.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherSpringer
dc.relation.ispartofpagefrom103
dc.relation.ispartofpageto117
dc.relation.ispartofissue1
dc.relation.ispartofjournalPharmacoEconomics - Open
dc.relation.ispartofvolume3
dc.subject.keywordsSocial Sciences
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsEconomics
dc.subject.keywordsHealth Care Sciences & Services
dc.titleInternational HTA Experience with Targeted Therapy Approvals for Lung Cancer
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationMaraiki, F; Byrnes, J; Tuffaha, H; Hinder, M, International HTA Experience with Targeted Therapy Approvals for Lung Cancer, PharmacoEconomics - Open, 2019, 3 (1), pp. 103-117
dcterms.licensehttps://creativecommons.org/licenses/by-nc/4.0/
dc.date.updated2019-09-20T02:48:13Z
dc.description.versionPublished
gro.rights.copyright© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
gro.hasfulltextFull Text
gro.griffith.authorTuffaha, Haitham W.
gro.griffith.authorMaraiki, Fatma
gro.griffith.authorByrnes, Joshua M.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record